Lakefront Biotherapeutics Quality Score
LKFT.XAMS
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Under 20x, reasonable relative to earnings
Negative FCF, no valuation support
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Net cash position, no leverage concern
15–20%, well above cost of capital
Lakefront Biotherapeutics (LKFT.XAMS) quality: score, margins and returns
Lakefront Biotherapeutics (LKFT.XAMS) scores 28/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100, on 61.6% operating margins and 15.5% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Lakefront Biotherapeutics (LKFT.XAMS) a high-quality business?+
Lakefront Biotherapeutics scores 28 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a 61.6% operating margin and a 15.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Lakefront Biotherapeutics's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LKFT.XAMS's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Lakefront Biotherapeutics scores well and where it falls behind.
What is Lakefront Biotherapeutics's return on invested capital (ROIC)?+
Lakefront Biotherapeutics earns about 15.5% on its invested capital, which is strong. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to LKFT.XAMS's margins and growth on this scorecard to judge durability.
How profitable is Lakefront Biotherapeutics?+
Lakefront Biotherapeutics runs an operating margin of about 61.6% and a net margin of about 60.2%. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with LKFT.XAMS
Held by ETFs
LKFT.XAMS is in 10 US ETFs. The largest of them, with LKFT.XAMS's weight in each:
Vanguard FTSE Europe ETFVGK0.01%of the fund
Vanguard FTSE All-World ex-US Small-Cap Index FundVSS0.04%of the fund
iShares Core MSCI Europe ETFIEUR0.01%of the fund
Schwab International Small-Cap Equity ETFSCHC0.06%of the fund
SPDR S&P International Small Cap ETFGWX0.08%of the fund
State Street SPDR Portfolio Europe ETFSPEU0.01%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LKFT.XAMS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.